Novel Rx
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
1 year 5 months ago
#Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger https://t.co/JHQHu91tud
Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
1 year 5 months ago
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies.
https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA.
In POS0009, Anang et al. studied T-cell receptor repertoire (…
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
Therapeutic development in pSS appears to…
Podcasts
ACR24 RA Panel Key Discussions on Rheumatoid Arthritis
ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis
ACR 2024 Rheumatology Roundup Featuring Drs. Artie Kavanaugh and Jack Cush
Poster Hall